M-Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
M-Pharma
Largest movements
- Stocks and contracts -€41,434
down €41,434 (-95.8%), from €43,255 to €1,822
- Receivables within one year +€8,366
up €8,366 (+183.1%), from €4,569 to €12,935
of which Other amounts receivable: +€6,776
- Cash -€2,840
down €2,840 (-71.7%), from €3,962 to €1,122
mainly Net result for the year (-€264,618) and Receivables within one year (-€8,366)
- Profit (loss) carried forward -€264,618
down €264,618 (-36.0%), from -€735,668 to -€1.0m
- Other debts +€121,316
up €121,316, from €0 to €121,316
- Trade debts +€53,796
up €53,796 (+502.6%), from €10,704 to €64,500
- Tax, wage and social debts +€53,598
up €53,598 (+657.5%), from €8,151 to €61,750
of which Remuneration and social security: +€53,575
- Turnover +€257,939
new in 2024: €257,939
- Gross operating margin -€97,775
down €97,775 (-221.1%), from -€44,212 to -€141,987
- Purchases and services +€73,477
up €73,477 (+21.7%), from €337,934 to €411,412
- Staff costs +€57,631
up €57,631 (+82.3%), from €69,986 to €127,617
- Financial income -€5,739
down €5,739 (-53.1%), from €10,808 to €5,069
From the 31-12-2023 result to the 31-12-2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 31-12-2023 and 31-12-2024 balance sheets and the 31-12-2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 31-12-2023 | 31-12-2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €51,787 | €15,879 | -€35,908 | -69.3% |
| Formation expenses | 20 | €0 | €0 | = | |
| Fixed assets | 21/28 | €0 | €0 | = | |
| Tangible fixed assets | 22/27 | €0 | €0 | = | |
| Plant, machinery and equipment | 23 | €0 | €0 | = | |
| Current assets | 29/58 | €51,787 | €15,879 | -€35,908 | -69.3% |
| Stocks and contracts in progress | 3 | €43,255 | €1,822 | -€41,434 | -95.8% |
| Stocks | 30/36 | €43,255 | €1,822 | -€41,434 | -95.8% |
| Amounts receivable within one year | 40/41 | €4,569 | €12,935 | +€8,366 | +183.1% |
| Trade receivables | 40 | €496 | €2,085 | +€1,590 | +320.9% |
| Other amounts receivable | 41 | €4,074 | €10,850 | +€6,776 | +166.3% |
| Cash at bank and in hand | 54/58 | €3,962 | €1,122 | -€2,840 | -71.7% |
| Total equity and liabilities | 10/49 | €51,787 | €15,879 | -€35,908 | -69.3% |
| Equity | 10/15 | €32,932 | -€231,686 | -€264,618 | |
| Contributions | 10/11 | €768,600 | €768,600 | = | 0.0% |
| Outside capital | 11 | €768,600 | - | -€768,600 | |
| Other | 1109/19 | €768,600 | - | -€768,600 | |
| Profit (loss) carried forward | 14 | -€735,668 | -€1,000,286 | -€264,618 | -36.0% |
| Amounts payable | 17/49 | €18,855 | €247,565 | +€228,710 | +1213.0% |
| Amounts payable after more than one year | 17 | - | €0 | = | |
| Financial debts | 170/4 | - | €0 | = | |
| Amounts payable within one year | 42/48 | €18,855 | €247,565 | +€228,710 | +1213.0% |
| Trade debts | 44 | €10,704 | €64,500 | +€53,796 | +502.6% |
| Suppliers | 440/4 | €10,704 | €64,500 | +€53,796 | +502.6% |
| Taxes, remuneration and social security | 45 | €8,151 | €61,750 | +€53,598 | +657.5% |
| Taxes | 450/3 | - | €24 | +€24 | |
| Remuneration and social security | 454/9 | €8,151 | €61,726 | +€53,575 | +657.2% |
| Other amounts payable | 47/48 | €0 | €121,316 | +€121,316 | |
| Turnover | 70 | - | €257,939 | +€257,939 | |
| Goods, raw materials, services and sundry goods | 60/61 | €337,934 | €411,412 | +€73,477 | +21.7% |
| Remuneration, social security and pensions | 62 | €69,986 | €127,617 | +€57,631 | +82.3% |
| Other operating charges | 640/8 | €1,742 | €334 | -€1,408 | -80.8% |
| Gross operating margin | 9900 | -€44,212 | -€141,987 | -€97,775 | -221.1% |
| Operating profit (loss) | 9901 | -€115,941 | -€269,938 | -€153,997 | -132.8% |
| Financial income | 75/76B | €10,808 | €5,069 | -€5,739 | -53.1% |
| Recurring financial income | 75 | €10,808 | €5,069 | -€5,739 | -53.1% |
| Financial charges | 65/66B | €794 | -€251 | -€1,045 | |
| Recurring financial charges | 65 | €794 | -€251 | -€1,045 | |
| Profit (loss) for the period before taxes | 9903 | -€105,927 | -€264,618 | -€158,691 | -149.8% |
| Profit (loss) for the period | 9904 | -€105,927 | -€264,618 | -€158,691 | -149.8% |
| Profit (loss) for the period to be appropriated | 9905 | -€105,927 | -€264,618 | -€158,691 | -149.8% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.